The cutaneous lymphocyte-associated antigen defines T lymphocytes with cutaneous tropism under inflammatory conditions. Bacterial infections participate in cutaneous inflammations, such as atopic dermatitis or psoriasis. Bacterial superantigens, such as staphylococcal enterotoxin B, can activate peripheral blood mononuclear cells to induce effector T cells bearing the T cell skin homing receptor cutaneous lymphocyte-associated antigen via enhancement of interleukin-12 production. We have identified and characterized the anti-inflammatory effects of different phosphodiesterase inhibitors on this system. Our data indicate that the selective type 4 phosphodiesterase inhibitor rolipram inhibits the Staphylococcal enterotoxin B-mediated generation of cutaneous lymphocyte-associated antigen positive
The cutaneous lymphocyte-associated antigen defines T lymphocytes with cutaneous tropism under inflammatory conditions. Bacterial infections participate in cutaneous inflammations, such as atopic dermatitis or psoriasis. Bacterial superantigens, such as staphylococcal enterotoxin B, can activate peripheral blood mononuclear cells to induce effector T cells bearing the T cell skin homing receptor cutaneous lymphocyte-associated antigen via enhancement of interleukin-12 production. We have identified and characterized the anti-inflammatory effects of different phosphodiesterase inhibitors on this system. Our data indicate that the selective type 4 phosphodiesterase inhibitor rolipram inhibits the Staphylococcal enterotoxin B-mediated generation of cutaneous lymphocyte-associated antigen positive L eukocytes extravasate into tissue by a multistep process involving different adhesion receptors, endothelial cell ligands, and chemoattractants (Butcher and Picker, 1996) . T lymphocytes are present in the cellular infiltration observed in chronic inflammation of different tissues and their traffic to particular tissues is regulated by the expression of specific T cell homing receptors (Butcher and Picker, 1996) . Thus, interaction between circulating homing receptorbearing T lymphocytes with ligands expressed by endothelium is essential in the multistep process of extravasation. There are three well characterized T lymphocyte homing receptors: L-selectin, α4β7 integrin and the CLA antigen. L-selectin mediates extravasation of T lymphocytes to high endothelial venules in lymph nodes by interaction with carbohydrate ligands found on peripheral lymph node addressins (Hemmerich et al, 1994) . The α4β7 integrin is found on T lymphocytes with nonrespiratory mucosal tropism, and endothelial binding is through interaction with the MAdCAM-1 molecule (Berlin et al, 1993) . Finally, the CLA antigen is a carbohydrate modification of the P-selectin glycoprotein ligand-1 (PSGL-1) (Fuhlbrigge et al, 1997) , which is preferentially expressed Manuscript received December 28, 1998; revised March 29, 1999 by memory T cells present in cutaneous inflammatory sites (Picker et al, 1990) . CLA ϩ cells are also present in peripheral blood mononuclear cells (PBMC) making 7-15% of the CD3 ϩ subset (Picker et al, 1990) . E-selectin is a ligand for CLA and it is found on activated endothelial cells and mediates transendothelial migration of CLA ϩ T cells (Picker et al, 1991) (Santamaria Babi et al, 1995a) and murine CD4 ϩ T cells into inflamed skin (Tietz et al, 1998) . In a hu-SCID mouse model grafted with human skin and human T cells it has been shown that CLA ϩ T cells migrate to human skin in vivo (Kunstfeld et al, 1997) . CLA ϩ T cells are related to specific immune responses in the skin because these cells preferentially respond to skin-associated antigens and their cytokine secretion reflects the cytokine pattern found in cutaneous inflamed lesions (Santamaria Babi et al, 1995b) . Moreover, the CLA antigen can be found in both Th1 and Th2 T cells (Teraki and Picker, 1997) . Of all the cytokines analyzed, interleukin 12 (IL-12) has been shown to be the most potent CLA inducing factor for T cells undergoing activation . As bacterial superantigens, which are very frequently found in skin inflammation, are potent inducers of IL-12 they may influence cutaneous inflammation by generating increased numbers of skin infiltrating T lymphocytes (Leung, 1995) .
Cyclic adenosine monophosphate (cAMP) has been shown to modulate inflammatory and immunologic processes (Bourne et al, 1974) . Phosphodiesterase (PDE) inhibitors increase intracellular cAMP by blocking cAMP conversion to 5ЈAMP. Of the nine PDE isozyme families that have been currently identified (Torphy, 1998) , type 4 phosphodiesterase (PDE 4) is the most abundant PDE isozyme in inflammatory cells (Torphy and Undem, 1991) . We have studied whether PDE 4 selective inhibitors may be useful as inhibitors of the superantigen Staphylococcal enterotoxin B (SEB)-mediated IL-12 production and skin-homing T cell induction. Our data indicate that cAMP elevating agents and in particular PDE4 inhibitors significantly inhibit CLA ϩ T cell generation by decreasing SEB-induced IL-12 production.
MATERIAL AND METHODS

Antibodies and reagents
The HECA-452 monoclonal antibody and rat immunoglobulin M were from Pharmingen (San Diego, CA). Anti-Lselectin conjugated to fluorescein isothiocyanate (FITC) and both mouse immunoglobulin G2b-FITC and immunoglobulin G1 isotype controls were from Serotec (Kidlington, U.K.). Anti-α4β7 monoclonal antibody (Act-1) was kindly provided by Dr. S. Shaw (National Cancer Institute, MA). Anti-CD3 conjugated to Phycoerythrin (PE) was from Becton Dickinson (San Jose, CA). Anti-CD14 conjugated to PE, normal mouse serum, goat-anti-mouse conjugated to FITC, N-2-O-dibutyryl-cAMP (DbcAMP) and PGE 2 were from Sigma (St. Louis, MO). Goat-antirat conjugated to FITC was from Immunotech (Marseilles, France). Rolipram [4-(3Ј-cyclopentyloxy-4Ј-methoxy-phenyl)-2-pyrrolidone] was synthesized by our medical chemistry department. Siguazodan and Zaprinast were a generous gift from SmithKline Beecham and Rhône-Poulenc Rorer, respectively.
Cell isolation and culture Human PBMC were isolated from venous blood from healthy donors by density gradient centrifugation over FicollPaque, from Pharmacia (Uppsala, Sweden). PBMC were then washed three times in phosphate-buffered saline from Biowhittaker (Verviers, Belgium) supplemented with 2% fetal bovine serum (Gibco, Paisley, U.K.) and resuspended in RPMI-1640 cell culture medium containing 10% fetal bovine serum, L-glutamine (2 mM), penicillin (100 U per ml) and streptomycin (100 µg per ml) all from Gibco. PBMC cells were stimulated with SEB (Sigma) as described . Briefly, PBMC at 1.2 ϫ 10 6 per ml were cultured in 48 well plates (Costar, Cambridge, MA) with SEB at a previously titrated optimal concentration of 0.1 µg per ml for 3 d at 37°C and 5% CO 2 . Lymphocytes were preincubated with compounds [rolipram, zaprinast, siguazodan, prostaglandin (PG) E 2 and DbcAMP] dissolved in dimethylsulfoxide or medium for 15 min prior to the addition of SEB. The concentrations of siguazodan and zaprinast used were above the IC 50 for PDE 3 and PDE 5, respectively. No vehicle effect was observed for the maximal dimethylsulfoxide concentrations used in our assays (0.005%). To measure IL-12 levels, cell supernatants were taken after 48 h culture and stored at -80°C until analyzed. The quantitation of IL-12 was done using the Quantikine Immunoassay for IL-12 from R&D Systems (Minneapolis, MN). In some experiments, exogenous human IL-12 (Pharmingen) was added simultaneously with SEB or medium.
Cell staining and flow cytometric analysis Four-parameter analysis was performed on a FACSCALIBUR flow cytometer (Becton Dickinson) installed with a power-pack equipped with an argon laser of 488 nm wavelength. Fluorescence 1 was measured using a 530 nm band pass filter, fluorescence 2 with a band pass filter of 585 nm and fluorescence 3 with a band pass filter of 650 nm. Typically, for immunofluorescence analysis, 5 ϫ 10 5 cells were sequentially stained with primary nonconjugated monoclonal antibody, goat-anti-rat conjugated to FITC or goat-anti-mouse conjugated to FITC, 2% normal mouse serum and anti-CD3 conjugated to PE. Stained cells were fixed in 2% paraformaldehyde in phosphatebuffered saline and stored at 4°C until analyzed. Specific staining was determined for each marker using appropriate isotype control antibodies. Cells were analyzed using the Cellquest software from Becton Dickinson. At day 0 analysis was performed gating only viable small lymphocytes. Analysis of SEB-activated populations at day 3 was performed gating small and T cell blast populations. integrin was measured on freshly isolated PBMC (day 0) and after 3 d of culture in the presence of 0.1 µg per ml SEB. As shown in Fig 1 for a representative experiment, after 72 h culture with SEB there is higher increase in the percentage of CLA ϩ CD3 ϩ lymphocytes (Fig 1B) than for L-selectin ϩ CD3 ϩ (Fig 1D) or α4β7 ϩ CD3 ϩ cells (Fig 1F) compared with their respective basal levels at day 0 (Fig 1A, C, E) . The percentages obtained are shown in the upper right side of the quadrants. A significant increase for CLA ϩ CD3 ϩ cells related to the other two homing populations after SEB activation was found in three independent experiments giving the following fold increases from basal values: CLA ϩ CD3 ϩ (3.5 Ϯ 0.09), L-selectin ϩ CD3 ϩ (0.63 Ϯ 0.26, p Ͻ 0.01) and α4β7 ϩ CD3 ϩ (1.6 Ϯ 0.038, p Ͻ 0.01).
Data analysis
cAMP elevating agents inhibit SEB-mediated induction of CLA ⍣ CD3 ⍣ cells To check the effect of agents known to act through the elevation of cAMP on the SEB-mediated CLA ϩ CD3 ϩ induction, PGE 2 , DbcAMP, or rolipram were added to the cultures 15 min prior to SEB stimulation. All three compounds significantly inhibited the generation of CLA ϩ CD3 ϩ cells as is shown in Fig 2. Furthermore, rolipram inhibited CLA ϩ CD3 ϩ cells generation in a concentration-dependent manner. The highest rolipram concentration tested (10 µM) showed a maximum inhibitory effect of 63.2% (p Ͻ 0.001 respect to untreated samples). A significant inhibition of 36.2% was also found for 1 µM rolipram (p Ͻ 0.005). Conversely, neither siguazodan (a selective PDE 3 inhibitor) nor zaprinast (a selective PDE 5 inhibitor) affected significantly the induction of CLA ϩ CD3 ϩ induced by SEB (Fig 3) . To characterize further the effect of rolipram on the induction of the CLA antigen we analyzed whether rolipram had any effect on the expression of PSGL-1, the protein backbone of CLA, in our experimental system. No effect of rolipram was found on PSGL-1 expression for a dose range of 0.1-10 µM (data not shown).
Inhibition of CLA ⍣ CD3 ⍣ T cell induction by rolipram is mediated by the suppression of IL-12 production Generation of CLA ϩ T cells after PBMC activation by SEB depends on the production of IL-12 . In order to characterize further the inhibitory effect of rolipram we harvested cell supernatants from 48 h PBMC cultured with SEB with or without inhibitors and IL-12 content was measured by enzyme-linked immunosorbent assay. As shown in Fig 4, rolipram inhibited in a concentrationdependent manner the SEB-mediated IL-12 production in four independent experiments. Rolipram at 10 µM reduced the amount of IL-12 detected to basal levels (p Ͻ 0.005). An 86% reduction in the IL-12 production was also found at a rolipram concentration of 1 µM (p Ͻ 0.01). Moreover, a parallel inhibition in the percentage of CLA ϩ T cells was also observed in the same subjects (data not shown).
Exogenous IL-12 reverts rolipram inhibition of SEBmediated CLA ⍣ CD3 ⍣ induction In order to check whether the effect of rolipram on the SEB-mediated CLA induction was due to an inhibition of IL-12, this cytokine was exogenously added together with SEB in a typical activation experiment. As it is shown in Table I , IL-12 could significantly revert, in a concentrationdependent manner, the effect of 10 µM rolipram in four independent assays (p Ͻ 0.05).
DISCUSSION
Bacterial superantigens potently induce polyclonal T cell activation and proliferation by simultaneously binding to certain Vβ elements of the T cell receptor (TcR) and the β chain of the major histocompatibility complex class II molecule present on the surface of antigen-presenting cells (Marrack and Kappler, 1990) . We have focused in this work on the regulation by cAMP elevating agents of the T cell activation induced by the SEB superantigen and, in particular, on the SEB-mediated induction of the human T cell skin homing receptor CLA from PBMC.
Our data indicate that these agents inhibit the SEB-mediated increase of skin homing T lymphocytes and that this effect depends on inhibition of IL-12 production. Bacterial infections are involved in chronic cutaneous inflammatory diseases, such as psoriasis or atopic dermatitis (Leung et al, 1993; Leung, 1995) . In these diseases, bacterial superantigens may contribute to exacerbate the inflammatory status by modulating cytokine production (Hemmerich et al, 1994) , inducing liberation of proinflammatory mediators and also by increasing the number of CLA ϩ skin homing T cells . In addition, SEB downregulates the expression of the mucosal T cell homing receptor on human activated T lymphocytes (Hernández-Caselles et al, 1996) and, as shown in the present paper, does not affect the expression of L-selectin. One of the cytokines induced by superantigen activation of antigen-presenting cells is IL-12. It has been shown that IL-12 is the most important cytokine involved in the induction of the skin homing receptor CLA (Leung et al, 1995) . IL-12 is mainly produced by antigen-presenting cells, macrophages and dendritic cells (Ma et al, 1997) . As the PDE 4 isozyme is present in monocytes we studied the effect of a PDE 4 inhibitor on CLA ϩ T cell generation induced by SEB. Our data indicate that rolipram dose-dependently inhibited the induction of CLA ϩ T cells up to a maximum of 60%, whereas PDE3 or PDE 5 inhibitors had no effect. This inhibition was likely to be due to the reduction of IL-12 production observed in the presence of rolipram. Additionally, IL-12 could revert the rolipram inhibitory effect, further suggesting that PDE 4 inhibition of CLA ϩ CD3 ϩ cell generation is mediated by IL-12 suppression.
It has been shown that cAMP enhancement by PGE 2 or DbcAMP inhibit IL-12 receptor expression and IL-12 responsiveness on T cells (Wu et al, 1998) . Those data indicate that in our system, rolipram might also be affecting T cells. Such a possibility, however, deserves further investigation.
It has recently been shown in animal models that rolipram can reduce IL-12 production in a mouse model of collagen-induced arthritis (Ross et al, 1997) and of diabetes (Ling et al, 1998) . Our data indicate that PDE 4 inhibitors, through IL-12 inhibition, may decrease the generation of new skin homing T lymphocytes and therefore reduce some of the effects of superantigens in the lesions. Interestingly, it has been shown that CLA ϩ T cell migration through activated endothelium in vitro can be inhibited by blocking the CLA/ E-selectin interaction (Santamaria Babi et al, 1995a) . Thus, PDE 4 inhibitors, by reducing the number of CLA ϩ T cells, may interfere in the recruitment of skin-homing T lymphocytes into the inflammatory sites. Bacterial superantigens preferentially expand T cell subsets bearing specific TcR Vβ segments (Hemmerich et al, 1994) . In the case of atopic dermatitis it has been shown that circulating CLA ϩ T lymphocytes from children with atopic dermatitis and Staphylococcus aureus infection express increased percentages of circulating CLA ϩ TcRVβ2 and TcRVβ 5.1. Interestingly, Vβ2 and Vβ5.1 segments are both recognized by SEB (Torres et al, 1998) .
A similar restrictive association has also been described in circulating skin homing T lymphocytes from psoriatic patients. 1 Moreover, allergen-specific T cell lines derived from atopic dermatitis patients display TcR associated with S. aureus derived superantigens, indicating that allergen may expands T cells which are susceptible to be further activated by S. aureus. 2 Taken together these data indicate that skin infiltrating T lymphocytes in atopic dermatitis can be influenced by bacterially derived products. The fact that PDE 4 inhibitors inhibit SEB activation and skin homing T cell generation may be relevant in limiting the bacterial effects occurring in cutaneous inflammatory disorders. It has been previously shown that DbcAMP inhibits IL-12 production by human dendritic cells (Panina-Bordignon et al, 1997) and that PGE 2 inhibits IL-12 production by lipopolysaccharide (LPS)-stimulated dendritic cells (Rieser et al, 1997) , IL-12 receptor expression, and IL-12 responsiveness (Wu et al, 1998) . Moreover pentoxyfilline, a nonselective PDE inhibitor suppresses IL-12 production by LPSstimulated human peripheral blood mononuclear cells (Moller, 1997) . The inhibitory effect mediated by a selective PDE 4 inhibitor on IL-12 production described in the present paper suggests that this type of compound may also play an important part in the treatment of allergic cutaneous inflammation.
Dendritic cells are the most powerful producers of IL-12, particularly when CD40-bearing dendritic cells interact with CD40 ligand present on the T lymphocyte surface, even in the absence of antigen recognition (Cella et al, 1996) . Additionally, Th2 lymphocytes can induce IL-12 production by dendritic cells (Vezzio et al, 1996) and in this way may upregulate the number of CLA ϩ Th2 lymphocytes. As CLA ϩ lymphocytes preferentially respond to cutaneous allergens (Santamaria Babi et al, 1995b) and regulate immunoglobulin E production through IL-4 and IL-13 (Santamaria Babi et al, 1995b; Akdis et al, 1997) these cells play an important part in the cutaneous allergic inflammation. Moreover, it has been shown that IL-12 may contribute to established Th2 responses by releasing IL-10 without inhibiting ongoing Th2 responses (Jeannin et al, 1996) . In this scenario, PDE 4 inhibitors may downregulate ongoing IL-12-mediated allergic inflammation. On the other hand, in chronic atopic dermatitis, a predominant Th1-type response with an increase in IL-12 production in the lesions is found (Hamid et al, 1996) . In such situations PDE 4 inhibitory effects on IL-12 production may also be beneficial.
The clinical efficacy of a selective PDE 4 inhibitor which shows anti-inflammatory effects in atopic dermatitis has been reported (Hanifin et al, 1996) . PDE 4 inhibitors, like rolipram, can inhibit antigen-induced proliferation and cytokine (IL-2, IL-4, IL-5, and interferon-γ) production (Essayan et al, 1994 (Essayan et al, , 1997 Torphy, 1998) . In addition, our data suggest that this type of compound may also be effective in controlling the superantigen-mediated chronic inflammation found in cutaneous inflammatory disorders by decreasing both the generation of new pathogenic effector skin homing T lymphocytes and the IL-12-mediated exacerbation of cutaneous inflammation.
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